Skip to main content

Advertisement

SpringerLink
Log in

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Purpose

New prognostic markers are needed for malignant melanoma. Inducible nitric oxide synthase (iNOS) and cyclooxygenase type 2 (COX-2) have been described to correlate with progression of melanoma. Moreover, activating mutations in BRAF/NRAS oncogenes are often detected in melanoma. The BRAF/NRAS mutation status and expression of COX-2 and iNOS were examined to compare their prognostic value for overall survival (OS) in stage III malignant cutaneous melanoma.

Experimental design

The expression of iNOS and COX-2 in metastatic lymph nodes from 21 rapidly progressing (OS from date of diagnosis of stage III disease ≤14 months) and 17 slowly progressing (OS ≥60 months) stage III cutaneous melanoma patients was examined by immunohistochemistry. The presence of BRAF/NRAS mutations was analyzed using direct DNA sequencing. χ2 exact trend test and logistic regression analysis were used for statistical analysis.

Results

Both iNOS (P = 0.002) and COX-2 (P = 0.048) alone significantly predicted OS. The BRAF/NRAS mutation status did not significantly differ between patient groups, although iNOS significantly (P = 0.013) correlated with BRAF mutation frequency. Furthermore, the odds ratio (OR) with respect to OS of iNOS (OR = 10.4) was higher than that of COX-2 (OR = 5.6) and was stable in the multivariate analysis of OS together with disease stage IIIB/C, ulceration, number of metastatic lymph nodes, and Breslow tumor thickness.

Conclusion

Our data show that iNOS is an independent and stronger prognostic factor for OS in stage III malignant cutaneous melanoma than COX-2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, Kumar R (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125:312–317

    PubMed  CAS  Google Scholar 

  2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001a) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648

    PubMed  CAS  Google Scholar 

  3. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A (2001b) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622–3634

    PubMed  CAS  Google Scholar 

  4. Bianchini F, Massi D, Marconi C, Franchi A, Baroni G, Santucci M, Mannini A, Mugnai G, Calorini L (2007) Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. Prostaglandins Other Lipid Mediat 83:320–328

    Article  PubMed  CAS  Google Scholar 

  5. Bogdan C, Rollinghoff M, Diefenbach A (2000) The role of nitric oxide in innate immunity. Immunol Rev 173:17–26

    Article  PubMed  CAS  Google Scholar 

  6. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P (2003) l-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24:302–306

    Article  PubMed  CAS  Google Scholar 

  7. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA (2005) Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 37:745–749

    Article  PubMed  CAS  Google Scholar 

  8. Chwirot BW, Kuzbicki L (2007) Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Res 17:139–145

    Article  PubMed  CAS  Google Scholar 

  9. Cianchi F, Cortesini C, Fantappie O, Messerini L, Sardi I, Lasagna N, Perna F, Fabbroni V, Di Felice A, Perigli G, Mazzanti R, Masini E (2004) Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 10:2694–2704

    Article  PubMed  CAS  Google Scholar 

  10. Clancy R, Varenika B, Huang W, Ballou L, Attur M, Amin AR, Abramson SB (2000) Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. J Immunol 165:1582–1587

    PubMed  CAS  Google Scholar 

  11. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147

    Article  PubMed  CAS  Google Scholar 

  12. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

    Article  PubMed  CAS  Google Scholar 

  13. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, Hauptmann S (2001) Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61:303–308

    PubMed  CAS  Google Scholar 

  14. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M, Mao JT (2003) Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res 37:138–162

    Article  PubMed  CAS  Google Scholar 

  15. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063–1073

    PubMed  CAS  Google Scholar 

  16. Dubois RN, Radhika A, Reddy BS, Entingh AJ (1996) Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110:1259–1262

    Article  PubMed  CAS  Google Scholar 

  17. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188

    PubMed  CAS  Google Scholar 

  18. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA (2006) Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 119:861–866

    Article  PubMed  CAS  Google Scholar 

  19. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA (2000) Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 6:4768–4775

    PubMed  CAS  Google Scholar 

  20. Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA (2006) Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 25:3956–3962

    Article  PubMed  CAS  Google Scholar 

  21. Gray-Schopfer VC, a Dias S, Marais R (2004) The role of B-RAF in melanoma. Cancer Metastasis Rev 24:165–183

    Article  Google Scholar 

  22. Hibbs JB Jr (1991) Synthesis of nitric oxide from l-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. Res Immunol 142:565–569 discussion 96–8

    Article  PubMed  CAS  Google Scholar 

  23. Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM (1988) Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157:87–94

    Article  PubMed  CAS  Google Scholar 

  24. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G (1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84:9265–9269

    Article  PubMed  CAS  Google Scholar 

  25. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000) Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60:184–190

    PubMed  CAS  Google Scholar 

  26. Kumar R, Angelini S, Hemminki K (2003) Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 22:9217–9224

    Article  PubMed  CAS  Google Scholar 

  27. Massi D, Franchi A, Sardi I, Magnelli L, Paglierani M, Borgognoni L, Maria Reali U, Santucci M (2001) Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 194:194–200

    Article  PubMed  CAS  Google Scholar 

  28. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720–724

    Article  PubMed  CAS  Google Scholar 

  29. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59:4356–4362

    PubMed  CAS  Google Scholar 

  30. Ostendorf T, Van Roeyen C, Westenfeld R, Gawlik A, Kitahara M, De Heer E, Kerjaschki D, Floege J, Ketteler M (2004) Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. J Am Soc Nephrol 15:2307–2319

    Article  PubMed  CAS  Google Scholar 

  31. Patrignani P, Tacconelli S, Sciulli MG, Capone ML (2005) New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev 48:352–359

    Article  PubMed  CAS  Google Scholar 

  32. Rao CV (2004) Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 555:107–119

    PubMed  CAS  Google Scholar 

  33. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, Antonia S, Ochoa JB, Ochoa AC (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64:5839–5849

    Article  PubMed  CAS  Google Scholar 

  34. Rousseau DL Jr, Gershenwald JE (2004) The new staging system for cutaneous melanoma in the era of lymphatic mapping. Semin Oncol 31:415–425

    Article  PubMed  Google Scholar 

  35. Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A (2001) Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res 61:318–326

    PubMed  CAS  Google Scholar 

  36. Satyamoorthy K, Li G, Van Belle PA, Elder DE, Herlyn M (2002) A versatile method for the removal of melanin from ribonucleic acids in melanocytic cells. Melanoma Res 12:449–452

    Article  PubMed  CAS  Google Scholar 

  37. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A (2006) Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25:3357–3364

    Article  PubMed  CAS  Google Scholar 

  38. Tang CH, Grimm EA (2004) Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 279:288–298

    Article  PubMed  CAS  Google Scholar 

  39. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41–44

    PubMed  CAS  Google Scholar 

  40. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S (1994) Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54:1352–1354

    PubMed  CAS  Google Scholar 

  41. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N (1998) Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 69:168–172

    Article  PubMed  CAS  Google Scholar 

  42. Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55:115–122

    Article  PubMed  CAS  Google Scholar 

  43. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R (2004) V599 EB-RAF is an oncogene in melanocytes. Cancer Res 64:2338–2342

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants to R.K. and J.H. from the Swedish Cancer Society, the Cancer Society of Stockholm, the European Union (Grants “ENACT” and “DC-THERA”), the Karolinska Institutet, and “ALF-Project” grants from the Stockholm City Council.

Conflict of interest statement

The authors have no financial conflict of interest.

Author information

Authors and Affiliations

  1. Department of Oncology and Pathology, Cancer Center Karolinska, R8:01, Karolinska University Hospital, Karolinska Institutet, 171 76, Stockholm, Sweden

    C. Christian Johansson, Suzanne Egyházi, Giuseppe Masucci, Helena Harlin, Dimitrios Mougiakakos, Isabel Poschke, Bo Nilsson, Liss Garberg, Rainer Tuominen, Diana Linden, Marianne Frostvik Stolt, Johan Hansson & Rolf Kiessling

Authors
  1. C. Christian Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suzanne Egyházi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Masucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helena Harlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dimitrios Mougiakakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Isabel Poschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bo Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Liss Garberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rainer Tuominen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Diana Linden
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Marianne Frostvik Stolt
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Johan Hansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Rolf Kiessling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rolf Kiessling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johansson, C.C., Egyházi, S., Masucci, G. et al. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother 58, 1085–1094 (2009). https://doi.org/10.1007/s00262-008-0631-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-008-0631-1

Keywords

Search

Navigation